SUDARSHAN CHEMICAL INDUSTRIES LTD. Q1 FY27 Results

Sudarshan Chemical's consolidated (primary basis) Q1 FY27 profit for the quarter rose to ₹103.4 Cr from ₹55.0 Cr a year ago (+88% YoY; owners' share ₹97.3 Cr vs ₹47.2 Cr, +106%), on revenue of ₹2,642.1 Cr, up a modest 5.4% YoY but down 5.3% QoQ from ₹2,789.9 Cr — the QoQ dip is a sequential normalisation off a strong March-quarter order push rather than a fresh demand signal, and is not the headline here since YoY is the primary read. Net margin expanded to ~3.9% from 2.2% a year ago, and segment EBITDA margin (per the Part II disclosure) improved to ~9.8% (₹258.8 Cr) from 7.7% (₹192.4 Cr), helped by cost of materials falling to ~51.6% of revenue from ~54.9% and a ₹6.1 Cr higher joint-venture profit contribution (₹13.2 Cr vs ₹7.1 Cr). No exceptional items hit either period, so reported and adjusted growth are the same — but the print absorbed ₹36.1 Cr of Heubach-related integration and restructuring costs embedded in opex, meaning underlying margin progress would look even stronger excluding that drag.

The standalone (India-only) entity tells a different story and the divergence is material: standalone revenue actually grew faster than consolidated at 27.5% YoY (₹677.4 Cr vs ₹531.2 Cr), yet standalone PAT fell 21% YoY to ₹57.8 Cr from ₹73.3 Cr. The gap is explained by a ₹62.6 Cr unfavourable foreign-exchange swing embedded in other expenses (a ₹5.7 Cr loss this quarter versus a ₹56.9 Cr gain in the year-ago quarter) — stripping that swing out, standalone opex growth (~19%) tracked broadly with revenue growth. Readers comparing the two statements should treat consolidated as the operative number; the standalone decline is a forex-timing effect, not a demand or cost-structure deterioration.

The stock went into the print at ₹1,044.7, down 2% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters.

On guidance: management's last concall projected Heubach EBITDA of $35 million for FY27 and $90-100 million over 3-4 years, with near-term demand described as cautiously watched given geopolitical uncertainty; this filing does not break out Heubach-specific quarterly EBITDA (only Pigments/Others segments are disclosed), so progress against that specific target cannot be verified from the statement itself — treated as unknown rather than assumed met. No management press release or commentary beyond the regulatory board-outcome letter was available for this filing, and no analyst consensus figure for this specific quarter's revenue or PAT could be sourced, so the print is also unscored against Street. Alongside results, the Board also approved in-principle internal restructuring to directly acquire the Company's existing 70.26% indirect stake in Sudarshan Colorants India Limited (formerly Heubach Colorants India) from intermediate Europe/Switzerland holding entities — a related-party, arm's-length, cash-funded reorganisation with no announced price or timeline and no control or operational impact, so no P&L effect this quarter.

Sudarshan Chemical's Q1 FY27 result lands on a critical juncture: after a year of intentional margin compression to integrate the Heubach Group and absorb customer-retention costs, the Street is watching for signals that operating leverage is beginning to flow through. Analyst consensus expects 15–20% PAT growth for FY27 as a whole, but that number is only real if Q1 shows momentum in EBITDA margins and gross-profit discipline from the unified business.

A strong Q1 would show EBITDA margin at or above 6.0–6.2%, revenue in the ₹2,350–2,450 Cr band, and PAT growth of 12–15% yoy, signalling that integration costs are winding down and pigment-business scale is working. A weak Q1 would flag margin compression below 5.8%, sluggish top-line growth (< 5% yoy), or PAT growth missing consensus, suggesting either integration drag persisting or customer pressure in standalone India business.

Yes, but with caveats. FY26 revenue more than doubled to ₹9,787 Cr on Heubach, but EBITDA margins compressed sharply as the company absorbed redundancy and customer-retention costs. This was deliberate and expected. What Street wants to see now is evidence that the cost base is normalising and that Sudarshan's cost-per-rupee-of-revenue is trending down. If Q1 shows margin holding or slight recovery, FY27 guidance (15–20% PAT growth) becomes credible. If margins stay under pressure, FY27 becomes a question mark.

Sudarshan Chemical is at an inflection point: the Heubach integration is 16 months in, cost absorption is winding down, and the Street is waiting for the unified business to prove it can deliver operating leverage. Q1 FY27 is the acid test. Watch for EBITDA margin recovery (from FY26's 6.0% toward 6.5%+), revenue run-rate confirmation (₹2,350+ Cr), and PAT growth that validates the 15–20% FY27 guidance. If margins are sticky at 5.8%–6.0% and PAT growth is in single digits, it signals integration drag persisting and Street targets may get reset down. A margin beat and top-line growth would confirm the bull case and likely drive the stock higher toward the ₹1,217–1,486 target band.